Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Myeloma
International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia"
February 10th, 2009
The Binding Site Limited ("The Binding Site" or the "Company"), a privately-owned specialist U.K. diagnostics company, announces the publication of the first international guidelines recommending first-line use of Freelite(TM) in the diagnosis and management of multiple myeloma, a cancer of cells in the bone marrow, and related plasma cell disorders. The guidelines were written on behalf of the International Myeloma Working Group ("IMWG"), led by Dr. A Dispenzieri, Division of Hematology and Division of Laboratory Medicine, Mayo Clinic, USA, and will be published in Leukemia, a leading haematology and oncology journal, in February 2009. Freelite is a...
Source: Cancer Weekly (2009-02-10)
|
